One target – multiple indications: a call for an integrated common mechanisms strategy

Ever-increasing research and development costs are putting constant pressure on the pharmaceutical industry to improve their efficiency. Efforts to increase the output of the research pipeline have yielded limited success. Traditionally, maximization of the value of a drug is attempted through life-...

Full description

Saved in:
Bibliographic Details
Published in:Drug discovery today 2007-12, Vol.12 (23), p.1025-1031
Main Authors: Nielsch, Ulrich, Schäfer, Stefan, Wild, Hanno, Busch, Andreas
Format: Article
Language:English
Subjects:
Biological and medical sciences
Efficiency, Organizational
General pharmacology
Medical sciences
Pharmaceutical technology. Pharmaceutical industry
Pharmacology - economics
Pharmacology - methods
Pharmacology. Drug treatments
Research - economics
Research Design
Substrate Specificity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Ever-increasing research and development costs are putting constant pressure on the pharmaceutical industry to improve their efficiency. Efforts to increase the output of the research pipeline have yielded limited success. Traditionally, maximization of the value of a drug is attempted through life-cycle management, which is initiated late in development, or when the drug is already on the market. Validated targets can be exploited further through development of a follow-up drug, which may offer advantages regarding safety or convenience. In this article, we propose to systematically evaluate the full therapeutic potential of a drug target, proprietary chemical lead structure, or drug candidate as broad and as early as possible and we call this the ‘common mechanism’ approach.
ISSN:1359-6446
1878-5832
DOI:10.1016/j.drudis.2007.10.004